| SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE |
As
of September 30, 2021, there were the following potentially dilutive
securities that were excluded from diluted net loss per share because their effect would be anti-dilutive:
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| Shares from the conversion of Series B Preferred Stock not inclusive of dividends |
|
|
9,431,250 |
|
| Shares from the conversion of Series E-1 Preferred Stock (subject to vesting in 2021 through 2023 and potential forfeiture) |
|
|
8,500,000 |
|
| Shares from common stock options |
|
|
1,112,619 |
|
| Shares from common stock warrants |
|
|
7,559,289 |
|
| Shares from the conversion of debentures |
|
|
218,750 |
|
| Shares from the conversion of redeemable convertible preferred stock (based upon an assumed conversion price at September 30, 2021 of $0.16 per share; inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
4,286,875 |
|
As
of September 30, 2020, there were the following potentially dilutive
securities that were excluded from diluted net loss per share because their effect would be anti-dilutive:
| Shares from common stock options |
|
|
468,619 |
|
| Shares from common stock warrants |
|
|
46,154 |
|
| Shares from the conversion of debentures |
|
|
66,000 |
|
| Shares that may be converted from Bridge Notes (based upon an assumed conversion price at September 30, 2020 of $1.98 per share) |
|
|
8,079,617 |
|
| Shares from the conversion of redeemable convertible preferred stock (inclusive of cumulative dividends which may be converted to shares of common stock under certain conditions). |
|
|
3,522,591 |
|
|
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| |
|
|
|
|
| Shares from the conversion
of Series B Preferred Stock |
|
|
1,756,250 |
|
| Shares from the conversion of Series
E-1 Preferred Stock (subject to vesting in 2021 through 2023 and potential forfeiture) |
|
|
7,650,000 |
|
| Shares from common stock options |
|
|
468,619 |
|
| Shares from common stock warrants |
|
|
46,154 |
|
| Shares from the conversion of debentures |
|
|
625,000 |
|
| Shares that may be converted from Bridge
Notes (based upon an assumed conversion price at December 31, 2020 of $0.22 per share) |
|
|
6,578,702 |
|
| Shares from the conversion of redeemable
convertible preferred stock (based upon an assumed conversion price at December 31, 2020 of $0.22 per share; not inclusive
of cumulative dividends which may be converted to shares of common stock under certain conditions) |
|
|
2,727,273 |
|
At
December 31, 2019, there were the following potentially dilutive securities that were excluded from diluted net loss per share
because their effect would be anti-dilutive (all shares adjusted to reflect a 25:1 reverse stock split effected on September 4,
2020):
| |
|
|
|
|
| Shares from common stock
options |
|
|
340,619 |
|
| Shares from common stock warrants |
|
|
126,154 |
|
| Shares from the conversion of debentures |
|
|
66,000 |
|
| Shares that may be converted from Bridge
Notes (based upon an assumed conversion price at December 31, 2019 of $2.10 per share); |
|
|
2,858,671 |
|
| Shares from the conversion of redeemable
convertible preferred stock (not inclusive of cumulative dividends which may be converted to shares of common stock under
certain conditions). |
|
|
299,442 |
|
|